Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)
Shots:
- The P-IV (ELEVATUM) trial assessed Vabysmo (Q4W until wk.20 then Q8W until wk.52) in underrepresented groups such as Black, African American, Hispanic/Latino with DME. Patients did not receive prior anti-VEGF treatment
- After 1yr., 124 patients were able to read added 12.3 letters on avg. (~2.5 lines on eye chart), with a vision gain of 14.1 letters among Hispanic & Latino patients (~3 lines) as well as 11.3 letters in African American & Black patients. Safety profile was well-tolerated without any new concerns
- Patients also experienced retinal drying with a significant decrease of 206.3 microns in central subfield thickness (CST). Findings aligned with the P-III (YOSEMITE & RHINE) DME trials; were highlighted at AAO 2024
Ref: Roche | Image: Roche
Related News:- Roche Highlights 2-Years Data from RAINBOWFISH Trial of Evrysdi for Treating Children with Spinal Muscular Atrophy (SMA) at WMS 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
